Business Context and Reporting Period
This Form 6-K filing by I-Mab (now NovaBridge Biosciences) covers the extraordinary general meeting (EGM) of shareholders held on October 24, 2025. The filing documents the submission of matters to a vote of shareholders, specifically regarding a corporate name change and amendments to the company's governing documents.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance filing and does not contain financial performance data.
Material Changes
- Corporate Name Change: Shareholders approved changing the English name from "I-Mab" to "NovaBridge Biosciences" and the dual foreign name from "天境生物" to "新桥生物".
- Governing Documents: Shareholders approved the Seventh Amended and Restated Memorandum and Articles of Association, replacing the previous sixth amended version.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the procedural results of the shareholder vote.
Important Facts for Investors
- Voting Participation: Approximately 34% of total outstanding shares (90,174,250 shares) were present or represented by proxy, constituting a quorum.
- Vote Results - Name Change: 90,149,771 votes For, 23,025 Against, 1,454 Abstain.
- Vote Results - Articles of Association: 90,142,346 votes For, 26,583 Against, 5,321 Abstain.
- Effective Date: The name change and new articles of association are effective as of the date the certificate of incorporation on change of name is issued by the Registrar of Companies in the Cayman Islands.